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ABSTRACT 
Tuberculosis (TB) has been identified as one of the most highly infectious diseases in the world. Tuberculosis can be identified as pulmonary or 
extrapulmonary. Therapy for TB is a combination of several drugs in one treatment. The effectiveness and toxicity of TB therapy may differ in each 
patient because of some risk factors, especially genetic variations. This review describes several genes that can affect the effectiveness and toxicity 
of antituberculosis drugs, namely UGT1A1, SLCO1B1, NAT2, and CYP2E1. This review was conducted utilizing the PubMed database, with keywords 
used as follows: polymorphism, antituberculosis, and tuberculosis. The presence of polymorphisms in these genes can result in hepatotoxicity and 
decreased drug bioavailability. Therefore, polymorphisms in these genes can determine the effectiveness of TB therapy. 
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INTRODUCTION 
Between a quarter and a third of the world’s population have been 
identified to be latently infected with Mycobacterium tuberculosis [1]. 
Approximately 1.2 million (around 1.1–1.3 million) tuberculosis 
(TB) deaths were recorded among Human Immunodeficiency Virus 
(HIV)-negative people in 2018 (a 27% reduction from 1.7 million in 
2000) and an additional 251,000 deaths (around 223,000–281,000) 
[2]. Most TB cases in 2018 are in the Southeast Asian region (44%), 
Africa (24%), and the Western Pacific (18%), while smaller 
percentages are determined to be in the Eastern Mediterranean 
(8%), America (3%), and Europe (3%). Eight countries accounted 
for two-thirds of the global total, namely India (27%), China (9%), 
Indonesia (8%), Philippines (6%), Pakistan (6%), Nigeria (4%), 
Bangladesh (4%), and South Africa (3%) [3]. The effectiveness of 
antituberculosis drugs can differ in each patient. At some point, 
these drugs can cause adverse reactions [4]. Some adverse reactions 
to antituberculosis drugs affect the outcomes of treatment and 
probably cause treatment failure. The predominant of adverse 
reactions were gastrointestinal disorders, drug-induced 
hepatotoxicity [5], musculoskeletal disorders, central dan peripheral 
nervous system disorders, and less vision disorder [6]. Some risk 
factors for decreased liver function are malnutrition, alcohol 
consumptions [7], and genetics factor [8]. Genetics factors that cause 
drug effects such as the presence of gene polymorphisms in patients. 
Genetic factors in patients can cause poor therapeutic outcomes as 
well as an increased risk of drug resistance [9]. 
A single nucleotide mutation, referred to as single nucleotide 
polymorphisms (SNPs), can cause such variations in drug response. 
SNPs occur when a nucleotide is substituted erroneously within an 
allele, which may be unique or common to many individuals in the 
human population. SNPs occur in a variety of DNA [10]. Based on 
current literature, genes that can affect the responses of drugs in TB 
patients are UDP-glucuronosyltransferase 1A1 (UGT1A1), solute 
carrier organic anion transporter family member 1B1 (SLCO1B1), N-
acetyltransferase 2 (NAT2), and cytochrome P450 2E1 (CYP2E1). 
UGT1A1 has been identified as a phase II drug metabolism enzyme 
that is important in conjugation and elimination of xenobiotics, 
carcinogens, and drugs [11–13]. The presence of polymorphisms in 
UGT1A1 causes a decrease in enzyme activity, resulting in 
pharmacokinetic differences from drugs [14]. SLCO1B1 is a gene that 
encodes transporters with a role in drug metabolism, specifically 
organic anion transporting polypeptide (OATP). Genetic variations 
of this gene can change the activity of transporters, leading to 
changes in pharmacokinetics and drug efficacy [15, 16]. NAT2 is a 
gene that codes for enzymes that activate and deactivate drugs. The 
polymorphism in this gene has been identified to be related to the N-
acetylation polymorphism, which determines fast, medium, and 
slow acetylator phenotypes. Polymorphisms in this gene are also 
associated with high drug toxicity [17]. CYP2E1 is a gene that codes 
for the cytochrome P450 enzyme, which catalyzes reactions in drug 
metabolism [18]. 
Methods 
This review included studies published in PubMed obtained using 
the keywords "polymorphism," "antituberculosis," and 
"tuberculosis." Additionally, annual reports released by the World 
Health Organization were included. However, reviews, non-English 
studies, and non-human studies were excluded. Of the 179 studies, 
we included 17 studies that focused on the relationship between 
gene polymorphisms and antituberculosis drugs, namely UGT1A1, 
SLCO1B1, NAT2, and CYP2E1 (fig. 1). 
 
 
Fig. 1: Flowchart of the literature search process 
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DISCUSSION 
The varying efficacy and toxicity of drugs are still identified to be a 
problem, causing harm to patients who are struggling to recover 
from their illness. Identifying the genetic differences in each patient 
can help the clinician adjust dosing and improve the results of 
therapy. This review further describes the influence of several genes, 
such as UGT1A1, SLCO1B1, NAT2, and CYP2E1, which might be 
associated with antituberculosis drug response (table 1). However, 
the results obtained from each population may be different. 
 
Table 1: Association gene polymorphisms with the responses of antituberculosis drugs 








Taiwanese There is an association between gene polymorphism and 
elevated antituberculosis drug-induced hepatotoxicity risk 
[19] 
 rs4148323 A/A 927 Chinese Gene polymorphism with A/A genotype significantly could 




445 Chinese No significant association between gene polymorphism and 




SLCO1B1*15 445 Chinese Patient with one haplotype of SLCO1B1*15 could have a higher 
risk of antituberculosis drug-induced hepatotoxicity than others 
with SLCO1B1*1a or SLCO1B1*1b 
[22] 





927 Chinese Patients with rs4149034 G/A, rs1564370 G/C, and rs2900478 
T/A polymorphism could have a lower risk of antituberculosis 
drug-induced hepatotoxicity. While a patient with rs2417957 
T/T and rs4149063 T/T polymorphism could have a higher risk 
of antituberculosis drug-induced hepatotoxicity 
[20] 
 rs4149013, rs4149014 
rs2306283, rs4149056 
226 Korean No association between gene polymorphism with the development 
of antituberculosis drug-induced hepatotoxicity risk 
[23] 
 rs4149032 rs11045819 174 Black African Did not explain variability in AUC0–∞ [24]  of rifampin 
 rs2306283 113 Ghanaian Patients with homozygous *1b variants (AA genotype) 
significantly decreased Cmax and AUC0–8h
[25] 
 of rifampicin 
compared to wildtype (GG genotype) 
NAT2 rs1041983 (282TT) 
rs1799930 (590AA) 
rs1799931 (857GA) 
208 Chinese Gene polymorphism could higher development of 
antituberculosis drug-induced hepatotoxicity 
[26] 
 rs1799930 (NAT2*6A) 241 Indonesian Gene polymorphism could higher development of 





408 Indian Gene polymorphism could higher development of 
antituberculosis drug-induced hepatotoxicity 
[28] 
 rs1799929 2244 Uyghur There is an association between genetic polymorphism and 
antituberculosis drug-induced hepatotoxicity higher in a patient 




66 Tunisian Polymorphism of rs1799929 (CC genotype) and rs1799930 (GG 
genotype) associated with decreasing antituberculosis drug-
induced hepatotoxicity, while rs1799929 (TT genotype) and 
rs1799930 (AA genotype) associated with a higher risk of 









113 Ghanaian Isoniazid doses and slow NAT2 genotype associated with Cmax 
and AUC0–8h
[25] 
 of isoniazid. Twelve patients recorded Cmax 
isoniazid values<3 g/ml (low) and 49 recorded participants had 
Cmax values>6 g/ml (high). Of the 12 patients with low Cmax, 
only 1 had a rapid NAT2 genotype (wildtype homozygote) and 2 
had a slow NAT2 genotype (variants homozygote). Of the 49 









30 Venezuelan AUC0-24 and t1/2 [31]  of isoniazid are statistically higher in slow 
acetylators (NAT2*5, *6, *7, *14) compared to genotypically 
rapid (NAT2*4, *12, *13) acetylators. Whereas the clearance was 
significantly lower in the slow acetylators compared with the 
rapid acetylators 
 rs4646244, rs4646267 
rs1799930, rs1799931 
221 Korean No association between NAT2 polymorphism with the 
antituberculosis drug-induced maculopapular eruption 
[32] 
CYP2E1 rs2031920 408 Indian Could have the risk of antituberculosis drug-induced 
hepatotoxicity development 
[28] 
 rs2031920 2244 Uyghur No significant association between polymorphism and 




445 Chinese No significant association between polymorphism and 
development of antituberculosis drug-induced hepatotoxicity 
[33] 
 rs2031920, rs2070672 
rs915908, rs8192775 
rs2515641, rs2515644 
445 Chinese No significant association between polymorphism and 
development of antituberculosis drug-induced hepatotoxicity 
[34] 
 rs2031920, rs2070672 
rs2070673 
221 Korean No association between CYP2E1 polymorphism with the 
antituberculosis drug-induced maculopapular eruption 
[32] 
 rs2031920 314 Indian Genotypic distribution of rs2031920 significantly higher in 
antituberculosis drug-induced hepatotoxicity than in the non-
antituberculosis drug-induced hepatotoxicity group 
[35] 
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UGT1A1 
UGT1A1, a gene in the UGT1A family, has been determined to code for 
UDP-glucuronosyltransferase. This enzyme catalyzes glucuronidation 
during phase II of drug metabolism, specifically conjugation. With it, 
various substances are processed, including estrogen, bilirubin, 
carcinogens, xenobiotics, and medications [11–13]. UGT1A1 is located 
on chromosome 2 at position 37.1 [36] (fig. 2). 
 
 
Fig. 1: Cytogenetic location of UGT1A1 [37] 
 
The presence of UGT1A1 polymorphism causes a decrease in enzyme 
activity, resulting in pharmacokinetic differences from drugs [14]. In 
Taipei, Taiwan, the UGT1A1 gene polymorphisms UGT1A1*27 
(686C>A) and UGT1A1*28 [(TA)6→(TA)7] are associated with 
antituberculosis drug-induced hepatotoxicity (ATDIH) [19]. In 
Shanghai, China, polymorphisms in rs4148323 A/A genotypes 
significantly reduce the risk of developing ATDIH [20]. However, in 
other populations in China, studies located outside Shanghai found 
that polymorphisms at rs4148323 and rs8330 had no significant 
effect on the risk of developing ATDIH [21]. 
SLCO1B1 
SLC (solute carrier family) is a transporter family that includes 
OATP [22, 23, 38]. This protein in hepatocytes facilitates hepatic 
uptake of compounds from the blood to be excreted [36]. In addition 
to transporting bile acids and other endogenous substances, OATP is 
also involved in the transportation of drugs [22, 23, 38]. OATP1B1 is 
an essential member of the OATP family and is found in the 
basolateral membrane of hepatocytes. Various drugs, including the 
first line anti TB drugs, rifampicin and rifabutin, are absorbed and 
transported via the hepatic portal system for uptake by OATP1B1, 
after which they will be metabolized and eliminated[38–40]. 
SLCO1B1, one of the genes that encode for the transporter, is 
situated in chromosome 12, in position 12.1[36] (fig. 3). 
Genetic variations of this gene can change the activity of 
transporters, leading to drug pharmacokinetic changes [15, 16]. 
Gene variations from the haplotype analysis show that patients who 
have at least one SLCO1B1*15 haplotype have a higher risk of 
developing ATDIH compared to those who have a SLCO1B1*1a or 
SLCO1B1*1b haplotype in populations in Zhejiang, Guangxi, 
Chongqing, Jilin, China [22]. Other results have shown that patients 
with SCLO1B1 polymorphisms rs4149034 G/A and rs2900478 T/A 
have a lower risk of ATDIH. On the other hand, patients in Shanghai, 
China, with rs2417957 T/T and rs4149063 T/T have an increased 
risk of developing ATDIH [20]. In Korea, polymorphisms at 
rs4149013, rs4149014, rs2306283, and rs4149056 did not show an 
association with the risk of developing ATDIH [23]. In Ghanaian 
populations, patients with homozygous *1b variants (rs2306283) 
(AA genotype) significantly decreased the Cmax and AUC0–8h of 
rifampicin compared to the wildtype (GG genotype) [25]. Another 
study showed that rs4149032 and rs11045819 on Black African 
populations did not explain any variability in the AUC0–∞
NAT2 
 of rifampin 
[24]. 
NAT2 codes for enzymes that activate and deactivate drugs [17]. N-
acetyltransferase is identified to be an enzyme mainly found in the 
liver to detoxify large amounts of chemical compounds. NAT2 has 
more than 23 variations to current knowledge [42s]. The 
polymorphism of this gene determines N-acetylation polymorphism, 
which can lead to fast, medium, and slow acetylator phenotypes. 
Polymorphism in this gene is also determined to be associated with 
cancer and higher drug toxicity [17]. NAT2 is on chromosome 8 at 
position 22 [43] (fig. 4). 
 
 
Fig. 2: Cytogenetic location of SLCO1B1 [41] 
 
 
Fig. 3: Cytogenetic location of NAT2 [43] 
 
Based on several studies, polymorphisms of this gene are associated 
with the risk of developing ATDIH in TB patients. A polymorphism in 
rs1799930 in a TB patient has been found to be associated with an 
increased risk of developing ATDIH in Beijing [26], Indonesia [27], 
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India [28], and Tunisia (AA genotype) [30]. In Tunisia, the GG 
genotype is associated with a decreased risk of ATDIH [30]. The 
rs1799931 gene polymorphism is associated with ATDIH in Beijing 
[26] and India [28]. Other polymorphisms at rs1041983 are 
associated with an increased risk of developing ATDIH in Beijing 
[26]. The rs1799929 gene polymorphism is associated with an 
increased risk of ATDIH in Indian [28], Tunisian (TT genotype) [30], 
and Xinjiang populations [29], while in Tunisian populations, the CC 
genotype was associated with a decreased risk of ATDIH [30]. 
Another study showed that rs1801279, rs1041983, rs1801280, 
rs1799929, rs1799930, rs1208, and rs1799931 were associated 
with changes in the Cmax and AUC(0–8h)  of isoniazid. Twelve patients 
recorded Cmax isoniazid values<3 g/ml (low), and 49 recorded 
participants had Cmax values>6 g/ml (high). Of the 12 patients with a 
low Cmax, only 1 was identified to have a rapid NAT2 genotype 
(wildtype homozygote), while 2 had a slow NAT2 genotype (variants 
homozygote). Of the 49 patients with high isoniazid Cmax, only 26 
were determined to have a slow NAT2 genotype (variant 
homozygote) [25]. Meanwhile, in Venezuelan populations with the 
genotypes NAT2*4, *5, *6, *7, *12, *13, and *14, the AUC0–24 and t1/2
CYP2E1 
 
of isoniazid were statistically higher in slow acetylators (NAT2*5, *6, 
*7, *14) compared to genotypically rapid (NAT2*4, *12, *13) 
acetylators. Conversely, the clearance was significantly lower in the 
slow acetylators compared with the rapid acetylators [31]. In Korea, 
the NAT2 polymorphisms at rs4646244, rs4646267, rs1799930, and 
rs1799931 had no association with antituberculosis drug-induced 
maculopapular eruption [32]. 
The CYP450 protein is a monooxygenase that catalyzes many of the 
reactions involved in drug metabolism. These enzymes metabolize 
endogenous or exogenous substrates [18]. CYP2E1 is one of the 
crucial enzymes in the metabolism of anti TB drugs, especially 
isoniazid. Several new studies were published regarding the 
relationship between CYP2E1 polymorphisms and ATDIH [26, 33, 
44–46]. One of these studies describes how gene polymorphism 
coding for CYP2E1 can affect enzyme activity as well as susceptibility 
to hepatitis induced by anti-TB drugs [47]. 
In India, polymorphisms at rs2031920 have a significant associated 
risk of developing ATDIH [28]. In China, there were no significant 
relationships between rs2031920 [29, 33], rs2070672, rs915908, 
rs8192775, rs2515641, rs2515644 [34], and rs6413432 [33] with 
the risk of developing ATDIH. Another study showed that CYP2E1 
polymorphism at rs2031920, rs2070672, and rs2070673 had no 
association with antituberculosis drug-induced maculopapular 
eruption in Korean populations [32]. In India, rs2031920 showed 
that significantly higher in antituberculosis drug-induced 
hepatotoxicity than in the non-antituberculosis drug-induced 
hepatotoxicity group [48]. 
In many of the studies above, genetic polymorphisms had an 
association with various anti TB drug responses, such as clearance, 
the risk of ATDIH, and the bioavailability of drugs (fig. 5), and can 
further lead to adverse outcomes. 
 
 
Fig. 4: Effect of gene polymorphisms on the responses of antituberculosis drugs 
 
CONCLUSION 
There are several differences in gene polymorphisms in each 
population. Some genes that can affect the effectiveness and toxicity 
of antituberculosis drugs are UGT1A1, SLCO1B1, NAT2, and CYP2E1. 
Polymorphisms in these genes can cause harm to TB patients. In 
UGT1A1, polymorphisms at rs4148323 and rs8330 have no 
significant association with ATDIH; rs4148323 A/A could reduce 
ATDIH risk; UGT1A1*27 (686C>A) and UGT1A1*28 [(TA)6→(TA)7] 
could elevate ATDIH risk. In SLCO1B1, polymorphisms at rs4149034 
G/A, rs1564370 G/C, and rs2900478 T/A are associated with a 
lower risk of ATDIH; rs2417957 T/T, rs4149063 T/T, and 
SLCO1B1*15 are related to a higher risk of ATDIH; rs4149013, 
rs4149014, rs2306283, rs4149056, and rs4149033 have no 
significant association with ATDIH; rs2306283 A/A significantly 
decreased Cmax and AUC0–8h of rifampicin; rs11045819 and 
rs414903 did not have a relationship with rifampicin's AUC0–∞ . In 
NAT2, polymorphisms at rs1801280, rs1799930, 1799931, 
rs1041983, and rs1799929 are related to an increased the risk of 
ATDIH; rs1801279, rs1041983, rs1801280, rs1799929, rs1799930, 
rs1208, and rs1799931 had observed variations in Cmax and AUC0–
8h
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 of isoniazid; rs4646244, rs4646267, rs1799930, and rs1799931 
had no association with antituberculosis drug-induced 
maculopapular eruption. In CYP2E1, polymorphisms at rs3813867, 
rs2031920, rs6413432, rs2070672, rs915908, rs8192775, 
rs2515641, and rs2515644 had no significant relationship with the 
risk of developing ATDIH; rs2031920, rs2070672, and rs2070673 
revealed no association with antituberculosis drug-induced 
maculopapular eruption. Therefore, personalized medicine that 
takes genetic polymorphisms into consideration is recommended in 
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